Tildrakizumab OverviewTildrakizumab (trade name Ilumya (US)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union. Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immun...
Read more Tildrakizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tildrakizumab
Recent Tildrakizumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 100mg/1ml
Other drugs which contain Tildrakizumab or a similar ingredient: (1 result)
- ILUMYA Tildrakizumab-asmn